- Home
- CHPT vs SANA Comparison
CHPT vs SANA Comparison
Compare CHPT & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- SANA
- Stock Information
- Founded
- CHPT 2007
- SANA 2018
- Country
- CHPT United States
- SANA United States
- Employees
- CHPT N/A
- SANA N/A
- Industry
- CHPT Industrial Specialties
- SANA Medicinal Chemicals and Botanical Products
- Sector
- CHPT Consumer Discretionary
- SANA Health Care
- Exchange
- CHPT Nasdaq
- SANA Nasdaq
- Market Cap
- CHPT 468.9M
- SANA 519.8M
- IPO Year
- CHPT N/A
- SANA 2021
- Fundamental
- Price
- CHPT $0.61
- SANA $1.50
- Analyst Decision
- CHPT Hold
- SANA Strong Buy
- Analyst Count
- CHPT 10
- SANA 5
- Target Price
- CHPT $1.69
- SANA $9.50
- AVG Volume (30 Days)
- CHPT 22.3M
- SANA 3.7M
- Earning Date
- CHPT 03-04-2025
- SANA 05-07-2025
- Dividend Yield
- CHPT N/A
- SANA N/A
- EPS Growth
- CHPT N/A
- SANA N/A
- EPS
- CHPT N/A
- SANA N/A
- Revenue
- CHPT $417,083,000.00
- SANA N/A
- Revenue This Year
- CHPT $14.08
- SANA N/A
- Revenue Next Year
- CHPT $26.64
- SANA N/A
- P/E Ratio
- CHPT N/A
- SANA N/A
- Revenue Growth
- CHPT N/A
- SANA N/A
- 52 Week Low
- CHPT $0.56
- SANA $1.49
- 52 Week High
- CHPT $2.44
- SANA $10.50
- Technical
- Relative Strength Index (RSI)
- CHPT 37.13
- SANA 28.89
- Support Level
- CHPT $0.56
- SANA $2.18
- Resistance Level
- CHPT $0.71
- SANA $2.43
- Average True Range (ATR)
- CHPT 0.05
- SANA 0.27
- MACD
- CHPT 0.00
- SANA -0.09
- Stochastic Oscillator
- CHPT 28.00
- SANA 0.66
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.